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 Epstein-Barr Virus (EBV) is a human herpesvirus that infects approximately 90% 
of the global human population.  Infection with EBV is associated with several diseases, 
such as Burkitt’s Lymphoma, nasopharyngeal carcinoma, and gastric carcinoma.  In both 
latent and lytic states, EBV produces gene products that interfere with normal host cell 
signaling mechanisms.  Promoter regions within the EBV genome contain binding sites 
for a variety of cellular transcription factors.  EBV also lacks the machinery necessary for 
synthesis of viral proteins, and therefore must exploit major cell signaling pathways for 
cap-dependent translation.  The PI3K–Akt–mTOR and MAPK pathways stimulate 
downstream targets to promote biogenesis.  EBV interaction with proteins in these 
pathways can result in uncontrolled cell growth, proliferation, and apoptosis resistance, 
potentially leading to carcinogenesis.  Previous research shows that under rapamycin-
induced inhibition of mTORC1, a major component of PI3K–Akt–mTOR pathway, EBV 
lytic protein production varies in a cell-type specific manner, suggesting that EBV 
utilizes these pathways differently among B cells and epithelial cells.  For this study, I 
investigated the molecular targets of EBV within these pathways to gain further insight 
into the mechanisms involved in synthesis of EBV lytic gene products.  The results show 
that EBV activates variable levels of proteins within the PI3K–Akt–mTOR and MAPK 
pathways in different cell types during lytic replication, the MAPK pathways are used as 
a major alternative pathway when mTORC1 is inhibited, and inhibition of the mTOR and 
MAPK pathways utilized by EBV does not attenuate viral replication.
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CHAPTER I 
 
INTRODUCTION 
 
 
Viruses and Cancer 
 
 There are certain viruses capable of infecting particular host cell-types for the 
lifetime of the host.  These sustained infections are achieved by the virus either by the 
production of viral proteins, which ensure retention of the viral genome in normal cellular 
mitotic divisions, or by integration of the viral genome into the host cell genome.  In 
either case, the mechanisms involved in viral persistency require a distinct host-virus 
interaction to evade host immune responses and cell death.  Oncovirus-infected host cells 
are at risk of developing genomic instability, alterations in DNA repair mechanisms, 
aberrant protein expression and activation, apoptosis resistance, and increased growth and 
proliferation1.  Such influences on host cellular pathways contribute significantly to 
carcinogenesis.  In fact, tumors associated with viral infection account for approximately 
20% of all human cancers1.  Oncoviruses accountable for this approximation include 
Hepatitis B and C virus (HBV and HCV, respectively), Human Papillomavirus (HPV), 
Human T-lymphotropic virus (HTLV), Merkel cell polyomavirus (MVC), Kaposi’s 
sarcoma-associated herpes-virus (KSHV), and Epstein-Barr virus (EBV)2.  Elucidation of
virus-host interactions and mechanisms of virus survival can lend insight into novel ways 
to treat the cancers with which each oncovirus is associated. 
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Epstein-Barr Virus (EBV) Overview and Disease Associations 
 Epstein-Barr virus (EBV, HHV-4) is a ubiquitous herpesvirus, persistently 
infecting approximately 90% of the global human population.  EBV is most frequently 
acquired via salivary exchange and the initial infection is the causative agent of infectious 
mononucleosis (IM).  Virus entry into epithelial and B cells causes the classic symptoms 
of IM, which typically occur approximately 5 weeks into infection.  Symptoms of IM 
include fatigue, fever, lymphocytosis, and adenopathy3.  During the initial infection 
period, EBV is in a lytic state where new virions are actively reproduced.  Over time, 
lytic infection drops off and the virus enters a latent state.  During latency, specific viral 
proteins are produced to ensure retention of the viral genome into newly synthesized 
mitotic daughter cells.  At any point during the host’s lifetime, the virus can switch from 
latency to reactivation of lytic reproduction3.  In either phase, EBV can produce viral 
proteins encoded by the EBV genome that can interact with cellular proteins and alter 
host-cell protein expression, potentially inducing apoptosis resistance, translocation 
events, cell immortalization, proliferation, and alterations in DNA damage repair 
pathways3.  These cellular responses to EBV are just a few examples of the characteristic 
properties necessary for carcinogenesis.  In fact, EBV’s discovery in 1964 was from 
Burkitt’s lymphoma (BL) tissue3.  Since then, an increasing number of associations 
between EBV and various malignancies have been identified.  EBV is not only associated 
with BL, but several diseases as well, such as nasopharyngeal carcinoma (NPC), gastric 
carcinoma, and other cancers and autoimmune disorders3.  While the precise underlying 
molecular mechanisms leading to cancer remain to be elucidated, EBV’s role as a potent 
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oncovirus is evident.  Because EBV resides permanently in epithelial cells and B cells for 
the lifespan of the host, the study of viral and host protein interactions is essential for 
disease intervention. 
 
EBV Structure and Genome 
The EBV virion (Figure 1 A) is approximately 200nm in diameter.  Linear double 
stranded DNA is enclosed in an icosahedral nucleocapsid that is surrounded by tegument 
proteins and a lipid envelope.  Projecting from the envelope are finger-like projections, 
called glycoproteins, which assist in viral attachment and entry.  Some essential 
glycoproteins include BMRF-2, gp350, gp220, gp42, and gH/gL4.  The EBV genome is 
approximately 172 KBP long, and codes for approximately 85 genes4.  For entry and lytic 
replication, the genome is linear in form (Figure 1 B).  During latency in the host cell, the 
DNA forms a circular episome in which the ends of the linear DNA are covalently linked 
(Figure 1 C).  Some important gene products encoded in the viral DNA include latent 
membrane proteins (LMP1/2), nuclear antigens (EBNAs), small nuclear RNAs (EBERs), 
and lytic proteins (BZLF1 or Z, and BRLF1 or R)4. 
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Figure 1. Epstein-Barr Virion Structure, Linear Viral Genome, and Circularized 
Episome. A) Virion. B) Linear genome. C) Episome. 
Images B and C adapted from Fields virology. Fields, B. N., Knipe, D. M., & Howley, P. 
M. (2013)
0 
A 
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EBV Entry and Replication
 Epithelial cell attachment and entry occurs via viral glycoprotein BMRF-2 
interaction with cellular β1 integrins.  Viral glycoproteins gH/gL trigger fusion with the 
host cell membrane, allowing nucleocapsid entry and nuclear transport of the viral 
genome.  For B cell attachment, viral glycoproteins gp350 and gp220 bind to cellular 
receptor CD21.  Viral protein gp42, complexed with gH/gL, interacts with cellular human 
leukocyte antigen (HLA) class II proteins, allowing viral envelope fusion with the 
cellular membrane and nucleocapsid entry to the cell5.  Nuclear pores allow EBV genome 
entry into the cell nucleus.  Should the virus become latent, the linear DNA circularizes 
into the episome and becomes tethered to host DNA via EBNA-1 proteins5.  Lytic 
replication requires linear viral DNA, and waves of transcription of essential genes must 
occur to complete a replication cycle.  Immediate early genes, BZLF1 (Z) and  
BRLF1 (R) encode proteins that serve as transactivators of virus replication, turning on 
the cascade of early and late genes required for virus replication6.  Expression of Z 
protein not only enhances expression of R, but also upregulates its own expression, 
consequently amplifying the signals necessary for expression of early and late genes5.  In 
the absence of Z and R gene products, subsequent steps of viral replication cannot occur.  
Upon synergistic activation via Z and R proteins, early genes initiate viral genome 
replication and subsequent late gene expression.  Late genes produce capsid proteins, as 
well as proteins involved with assembly and budding of progeny virions5.  Because Z 
protein expression can trigger expression of R protein and succeeding early and late 
genes, the Z gene must be tightly regulated in the latency program.  Silencing of the Z 
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gene is accomplished using both cellular proteins and viral regulatory elements, such as 
cellular histone deacetylases and viral gene methylation sites5,6.  Histone acetylation is 
crucial for Z gene activation, and Z protein preferentially binds methylated response 
elements of lytic cycle gene promoters4,7.  EBV can alternate between latent and lytic 
states at any point during the host life span, and lytic activation can occur via a variety of 
stimuli, such as oxidative stress, inflammation, or hypoxia6.  Latently infected EBV cells 
can also be chemically induced into lytic replication in vitro using a variety of chemical 
agents.  Histone deacetylase inhibitors, such as sodium butyrate, can stimulate Z gene 
activation4.  Also, 12-O-tetradecanoylphorbol-13-acetate (TPA) can stimulate Z protein’s 
full transactivation functionality by inducing phosphorylation of Z protein’s SER186 via 
protein kinase C (PKC)6.  
 The promoter regions for both Z and R genes contain binding sites for a variety of 
cellular transcription factors.  Such interactions not only stimulate the switch from viral 
latency to lytic reproduction, but can also alter cellular protein activity and consequently 
stimulate various cell signaling pathways.  The Z promoter (Figure 2 A) contains regions 
of binding sites for the abundant cellular transcription factors Sp1/Sp3, myocyte enhancer 
factor 2D (MEF2D), cAMP Response Element-Binding protein (CREB), SMADs, 
activating transcription factors (ATFs), and the dual-functioning activator/repressor 
protein, Yin Yang 1 (YY1)4,8,9.  The R promoter (Figure 2 B) contains binding sites for 
the ubiquitous cellular transcription factors nuclear factor 1 (NF1), early growth response 
protein 1 (EGR-1), Sp1/Sp3, B-lymphocyte-induced maturation protein (BMP1), and 
activator/repressor protein, Yin Yang 1 (YY1)4,8,9.  These transcription factors that bind Z 
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and R promoters are downstream proteins of several major cell signaling cascades, such 
as the protein kinase C (PKC), mitogen activated protein kinase (MAPK), transforming 
growth factor (TGF-β), phosphatidylinositol-3-kinase (PI3K), and ataxia telangiectasia 
mutated (ATM) pathways4,8,9,10.  EBV lytic-reproduction-induced aberrant protein 
activity in these pathways can potentially promote genomic instability, cell growth, and 
cell cycle progression, all of which can contribute to carcinogenesis9,10.  
 
 
 
Figure 2. Promoter Regions for BZLF1 and BRLF1. 
A) BZLF1. B) BRLF1. Schematic images highlight binding sites for key cellular 
transcription factors. Images not to scale. 
(A) Image adapted from Fields virology. Fields, B. N., Knipe, D. M., & Howley, P. M. 
(2013). (B) Image adapted from Kenney, S. C., & Mertz, J. E. (2014, June). Regulation 
of the latent-lytic switch in Epstein–Barr virus. In Seminars in cancer biology (Vol. 26, 
pp. 60-68). Academic Press.
 A 
B 
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EBV Dependence on Host Translational Machinery  
 Like all viruses, EBV lacks the critical apparatus for synthesis of viral proteins.  
For survival, evolution, reproduction, and ability to spread to new hosts, viruses must 
exploit host cellular translational machinery for production of vital gene products11.  EBV 
and all other mammalian DNA viruses must maintain cap-dependent translation and are 
therefore reliant on major cell signaling pathways that stimulate key proteins that bind the 
5’-end of mRNA molecules12.  The phosphatidylinositol 3′‑kinase–Akt–mechanistic 
target of rapamycin (PI3K–Akt–mTOR) is a major cell signaling pathway that activates 
key proteins involved in macromolecule synthesis, making it a common target pathway 
for viruses to manipulate.   
The PI3K-Akt-mTOR pathway (Figure 3) is continuously used by cells to 
integrate a diverse array of nutritional and environmental signals to promote cell growth, 
metabolism, proliferation, protein synthesis, and cell survival13.  The pathway is activated 
through a variety of stimuli, such as cytokines, growth factors, integrins, and hormones.  
Receptor-mediated activation occurs when receptor tyrosine kinases (RTKs) receive a 
signal which triggers dimerization and autophosphorylation12.  Insulin receptor substrate 
1 (IRS1), an adaptor protein, binds phosphotyrosine and activates PI3K.  PI3K then 
phosphorylates phosphatidylinositol-4,5-bisphosphate (PIP2), converting it to 
phosphatidylinositol-3,4,5-triphosphate (PIP3)12.  This conversion recruits Akt and PDK1 
to the membrane, positioning Akt for phosphorylation by PDK112.  Akt can 
phosphorylate and activate a variety of targets14.  In the PI3K-Akt-mTOR pathway, Akt 
phosphorylates tuberous sclerosis 1 and 2 (TSC1/2) which is a complex that negatively 
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regulates Rheb-GTP by stimulating cellular GTPases12.  TSC1/2 loses inhibitory function 
upon phosphorylation via Akt, and Rheb-GTP activates the mTORC1 complex12.  
mTORC1 and mTORC2 are the two functionally discrete complexes at the heart of this 
pathway.  Each complex contains a unique set of subunits along with the catalytic 
subunit, mTOR, a serine threonine kinase that phosphorylates a variety of targets.  The 
mTORC2 complex is the minor player in this pathway, and less is known about its 
functionality.  It is known that mTORC2 regulates insulin signaling via IRS1 and 
promotes cell survival via activation of Akt15.  mTORC1 is a positive regulator of protein 
synthesis via phosphorylation of downstream effectors13.  Major targets of mTORC1 are 
p70S6K and the eIF4E binding protein (4EBP1).  Upon phosphorylation, p70S6K 
phosphorylates targets that promote cap-dependent translation, ribosome production, and 
translation elongation16.  In its unphosphorylated state, 4EBP1 is bound to and inhibits 
eukaryotic translation initiation factor (eIF4E).  Phosphorylation of 4EBP1 via mTORC1 
prevents binding to eIF4E, thereby enabling eIF4E to participate in cap-dependent 
translation16.   
Because the PI3K-Akt-mTOR pathway promotes protein synthesis, cell growth, 
metabolism, survival, and proliferation, it is commonly implicated in cancer.  Recent 
studies show increased levels of phosphorylated mTOR in gastric carcinoma, increased 
levels of phosphorylated Akt in undifferentiated versus differentiated non-keratinizing 
nasopharyngeal carcinoma, and increased phosphorylated p70S6K in lymphoma 
cells17,18,19.  Moreover, recent genomic profiling of nasopharyngeal carcinoma (NPC) 
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links expression of EBV viral genes and upregulated mTOR pathway activity to the 
enhancement of malignant properties of NPC20.  
 
 
 
Figure 3. The Phosphatidylinositol 3’-Kinase-AKT-Mechanistic Target of 
Rapamycin (PI3K-Akt-mTOR) Pathway. 
 
  
Therapeutic intervention through inhibition of the PI3K–Akt–mTOR signaling 
pathway could prove to be a promising strategy in the treatment of certain cancers.  
Rapamycin is a well-known macrolide compound that selectively inhibits mTORC1.  The 
compound is an antifungal metabolite produced by the soil bacterium Streptomyces 
hygroscopicus in the soil of Rapa Nui.  Rapamycin specifically inhibits mTORC1 by 
complexing with the 12 kDA FK506-binding protein (FKBP12) and acting as an 
allosteric inhibitor of mTOR in the mTORC1 complex, thereby preventing 
phosphorylation of downstream targets21.  Recent studies have shown suppression of 
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invasion protein MMP-2 in nasopharyngeal cancer stem cells, as well as improved 
antitumor effects of ionizing radiation when treating NPC22,23 Another recent study found 
that rapamycin treatment significantly inhibited tumor development and splenomegaly in 
a transgenic murine model of EBV-related Burkitt’s lymphoma24.  While these studies 
sound promising, rapamycin treatment for cancer and EBV-associated diseases has 
disadvantages.  For example, the compound is a potent immunosuppressant by inhibiting 
B and T cell proliferation21.  Additionally, studies in our lab have shown that rapamycin 
attenuates EBV lytic protein translation in a cell-type specific manner.  Rapamycin 
decreases EBV lytic replication in B cells, but increases EBV lytic gene expression in 
epithelial cells25. 
EBV’s ability to persistently produce lytic gene products and even increase viral 
protein synthesis in the absence of a fully functional PI3K–Akt–mTOR pathway despite 
mandatory necessity for cap-dependent translation is suggestive of another cellular 
signaling pathway at play.  Parallel to the PI3K–Akt–mTOR pathway are the Mitogen 
activated protein kinase (MAPK) pathways (Figure 4).  Similar to the PI3K–Akt–mTOR 
pathway, the MAPK pathways are comprised of kinases responsible for protein synthesis, 
metabolism, cell growth, survival, and proliferation26.  Key MAPK proteins include Ras, 
a small GTP-binding protein, extracellular signal-regulated kinase 1/2 (ERK 1/2), p38, 
and MAPK-interacting kinases (Mnk1/2)27.  Mnk1 and Mnk2 each exist as two isoforms, 
Mnk1a and 1b, and Mnk2a and 2b27.  These isoforms are produced via alternative 
splicing.  Mnk1a and Mnk2a contain binding sites for MAPK proteins and are generally 
localized in the cytoplasm, while Mnk1b and Mnk2b are dispersed in the nucleus and 
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cytoplasm27.  Mnk2a has a greater affinity for ERK and also has a high basal activity.  
Mnk1b and Mnk2b lack MAPK binding sites and also do not contain nuclear export 
sequences28.  The Mnks are key downstream targets of the MAPK proteins p38 and ERK 
and play an important role in regulation of eIF4E.  Phosphorylation of eIF4E via the Mnk 
kinases enables cap-dependent translation28.  Because eIF4E is a common target of the 
PI3K–Akt–mTOR and MAPK pathways, it is likely for viruses reliant on cap-dependent 
translation to stimulate either pathway.  
 
 
 
Figure 4. The Mitogen Activated Protein Kinase (MAPK) Pathways. 
13 
 
Raf Kinase Inhibitor Protein (RKIP) 
 A negative regulator of the MAPK pathway Raf/MEK/ERK is the metastasis 
suppressor Raf kinase inhibitor protein (RKIP, Figure 5).  RKIP is a 23 kDa cytosolic 
protein that binds specifically to Raf.  RKIP-Raf binding is an event which dissociates the 
Raf/MEK complex, competitively inhibiting MEK phosphorylation, thereby decreasing 
downstream activation of Mnk1/2 and eIF4E29.  RKIP is highly abundant in cells and has 
additional target pathways.  Several key targets influenced by RKIP include NF-κβ, 
GPCR, and GSK3β30.  In the NF-κβ pathway, RKIP interferes with Iκβ kinase (IKK), an 
upstream regulator of IKB.  This interaction prevents dissociation and ubiquitination of 
IKB from NF-κβ, thus preventing NF-κβ from nuclear translocation and activation of 
target genes29.  RKIP can also be phosphorylated via protein kinase C (PKC), which 
deactivates RKIP as a Raf inhibitor and allows phosphorylated RKIP to inhibit G-protein-
coupled-receptor kinase 2 (GRK2), a modulator of G-protein coupled receptors 
(GPCRs)30.  GPCRs are known to stimulate signal transducers and activators (STATs).  
RKIP also inhibits p38 activation of glycogen synthase kinase 3β (GSK3β)31.   GSK3β is 
a kinase involved in several pathways that regulate proliferation, apoptosis, and glucose 
regulation31.  Being a metastasis suppressor, RKIP is a multifunctional modulator of 
many pathways that lead to transcription, translation, biogenesis, and cell survival.  
However, RKIP’s role in cancer is not well known and clearly defined.  Studies have 
shown that downregulated RKIP and increased phosphorylated-RKIP are both common 
in metastatic tissues29,30,31.  Few studies have been conducted to evaluate RKIP and 
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phosphorylated-RKIP levels in relation to EBV latent and lytic states or EBV associated 
cancers.  
 
 
 
Figure 5. Raf Kinase Inhibitor Protein (RKIP) Pathway Interactions. 
Image adapted from Ling, H. H., Mendoza-Viveros, L., Mehta, N., & Cheng, H. Y. M. 
(2014). Raf kinase inhibitory protein (RKIP): functional pleiotropy in the mammalian 
brain. Critical Reviews™ in Oncogenesis, 19(6). 
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Aims of Study 
 Previous studies in our lab have shown that inhibition of the mTORC1 complex 
of the PI3K-Akt-mTOR cell signaling pathway has differential effects on EBV lytic 
protein production amongst infected B cells and epithelial cells, suggestive of a cell-type-
specific and multiple-pathway approach to translation of key lytic viral proteins.  It is 
well established that EBV is associated with several diseases where aberrant protein 
activity is a contributing factor.  Identification of the major cell signaling pathways and 
specific proteins being modulated for viral self-survival and replication can lead to a 
greater understanding of the mechanisms involved in EBV-induced diseases, potential 
attenuation of viral protein production, and the development of targeted therapies.  The 
goals of this study are as follows: in depth investigation of protein activation within the  
PI3K-Akt-mTOR and MAPK pathways with and without mTORC1 inhibition when EBV 
is lytic; use of MEK and p38 inhibitors in combination with mTORC1 inhibition to 
further investigate protein activation within the PI3K-Akt-mTOR and MAPK pathways 
and evaluate the possibility of attenuation of lytic protein production; and investigate 
what role, if any, RKIP and phosphorylated RKIP may have in the production of EBV 
viral proteins when mTORC1 is inhibited.  Flow cytometric analysis and immunoblotting 
techniques will be used to complete these aims of study.
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CHAPTER II 
 
MATERIALS AND METHODS 
 
 
Cell Culture and Inhibitor Treatment 
 
 Raji, an EBV positive Burkitt’s lymphoma cell line was grown in Thermo 
Scientific’s RPMI liquid media.  AGS-BDNeo, and EBV positive adenocarcinoma cell 
line was grown in Thermo Scientific’s Ham’s F-12 liquid media.  To maintain cellular 
retention of the viral episome in the epithelial cells, 500µg/mL of neomycin (G418) 
obtained from MP Biomedicals, LLC was added to the liquid media.  Both RPMI and F-
12 media was enriched with 10% fetal bovine serum (Gibco; Thermo Scientific), as well 
as 10µL/mL of fungicide, penicillin, and streptomycin.  Cell culture was maintained at 37 
degrees Celcius with 5% CO2.  EBV lytic replication was induced with the HDAC 
inhibitor, 12-O-tetradecanoylphorbol-13-acetate (TPA), and sodium butyrate (NaB).  Raji 
cells were treated with 20ng/mL of TPA and 3 mM NaB.  Due to sensitivity to HDAC 
inhibitor treatment, AGS-BDNeo cells were treated with 5ng/mL TPA and 0.75mM NaB.  
For inhibition of mTORC1, cells were treated with 5nM rapamycin (Sigma Aldrich) 24 
hours prior to induction.  For inhibition of p38 and MEK, cells were treated 30 minutes 
prior to induction with 10µM SB203580 and 10µM UO126, respectively (Cell 
Signaling).  Experimental conditions with mTORC1, p38, and MEK inhibitor treatments 
listed in Tables 1 and 2.   
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Cell Fixation and Flow Cytometric Analysis 
 Harvested cells from biological triplicates were washed in 1x phosphate-buffered 
saline (PBS) and fixed in 60% acetone at 4 degrees Celsius for 10 minutes.  Following 
fixation, cells were washed with 0.3% bovine serum albumin (BSA) (Fisher Scientific) 
dissolved in 1x PBS.  Subsequently, cells were resuspended in 100µL primary antibody 
(Table 3) diluted 1:200 in 1x PBS, 0.3% BSA, 5% donkey serum, and 0.10% Triton-X 
(incubation mix) and incubated for one hour at 23 degrees Celsius.  Afterwards, cells 
were washed with the PBS+BSA mixture and resuspended in 100µL secondary antibody 
(Table 3) diluted 1:400 in incubation mix.  After one-hour incubation period at 23 
degrees Celsius, cells were washed again in PBS+BSA and resuspended in 500µL PBS.  
Z protein was detected using secondary antibody Alexa 488 fluorophore (Jackson 
Immunoresearch).  Phosphorylated proteins of interest within cell signaling pathways 
were detected using secondary antibody CY5 fluorophore (Jackson Immunoresearch).  
Sample protein expression was quantified using the inCyte module for the Guava 
easyCyte 6-2L benchtop flow cytometer. 
 
Protein Extraction, SDS-PAGE, and Immunoblot 
 Cells from biological triplicates were harvested and suspended in lysis buffer 
containing 150mM NaCl, 5mM EDTA, 0.1% NP-40, 50mM pH 7 HEPES, and Thermo 
Scientific’s protease/phosphatase inhibitor (1:100 dilution).  After two freeze-thaw cycles 
at -80 degrees Celsius and 37 degrees Celsius, suspension was centrifuged at 4 degrees 
Celsius for 10 minutes to remove cellular debris.  Extract protein concentration was 
determined via Bradford assay and approximately 20-40µg were loaded.  Proteins were 
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separated on a 10% SDS-PAGE gel at 200V.  Upon completion, proteins were transferred 
to a Millipore Immobilon-PDVF membrane overnight at 100mA.  Once complete, 
membranes were blocked with 0.25% milk block/PBS containing 0.1% Fisher Scientific 
Tween 20.  Blots underwent washes and detection reactions in a Millipore SNAP i.d. 2.0 
Protein Detection System.  Blots were incubated with appropriate antibodies (Table 3), 
washed 4x in western wash containing 1x PBS and 0.1% Tween 20, and incubated with 
the appropriate secondary antibody (Table 3) for 10 minutes.  Blots were washed 4x with 
western wash and exposed to an enhanced chemiluminescent (ECL) substrate (Advansta) 
for 5 minutes.  Chemiluminescent imaging was completed using LI-COR Biosciences c-
digit blot scanner.  
 
Data Analysis 
Each flow cytometric and immunoblot experiment was performed in biological 
triplicate.  Western blot protein bands were quantified using Image Studio Digits 
software.  Flow cytometric sample analyses were conducted at 1000 events.  Flow 
cytometric output was gated on histogram and scatterplot (red CY5 versus green 488) 
regions at the end of background signal; any signal beyond background was recorded as 
positive for proteins of interest in percent of total cells.  Double positive percent of cells 
are red and green fluorescent cells present in the 1st scatterplot quadrant.  Cells positive 
for phosphorylated cellular proteins of interest are red fluorescent cells present in the 2nd 
scatterplot quadrant.  Cells positive for Z protein are green fluorescent cells present in the 
4th scatterplot quadrant.  All data represent means ± SD from biological triplicates.  
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Statistical significance of results was determined by two-tailed student T-test with a 
significant p-value <0.05. 
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Table 1. Treatment Conditions for mTORC1 Inhibition Experiments. 
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Table 2. Treatment Conditions for mTORC1, P38, and MEK Inhibition 
Experiments. 
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Table 3. List of Antibodies Used for Flow Cytometric Analysis and Immunoblotting. 
 
Antibody Source Primary/Secondary? Use 
EBV Zebra (BZ1) 
(mouse) 
Santa Cruz Primary Flow cytometry, 
Immunoblotting 
Goat-anti-mouse HRP Jackson 
Immunoresearch 
Secondary Immunoblotting 
Goat-anti-rabbit HRP Jackson 
Immonoresearch 
Secondary Immunoblotting 
α-tubulin (mouse) Santa Cruz Primary Immunoblotting 
RKIP (rabbit) Cell Signaling Primary Flow cytometry, 
Immunoblotting 
p-RKIP (rabbit) Santa Cruz Primary Flow cytometry, 
Immunoblotting 
p-mTORC1 (rabbit) Cell Signaling Primary Flow cytometry 
p-MEK (rabbit) Cell Signaling Primary Flow cytometry 
p-Mnk1/2 Cell Signaling Primary Flow Cytometry 
p-ERK (rabbit) Cell Signaling Primary Flow cytometry 
p-AMPK (rabbit) Cell Signaling Primary Flow cytometry 
p-p38 (rabbit) Cell Signaling Primary Flow cytometry 
p-TSC2 (rabbit) Cell Signaling Primary Flow cytometry 
p-4EBP1 (rabbit) Cell Signaling Primary Flow cytometry 
p-elF4E (rabbit) Cell Signaling Primary Flow cytometry 
p-p70S6K (rabbit) Cell Signaling Primary Flow cytometry 
p-AKT1/2/3 (mouse) Santa Cruz Primary Flow cytometry 
Donkey-anti-mouse 488 Jackson 
Immunoresearch 
Secondary Flow cytometry 
Donkey-anti-rabbit cy5 Jackson 
Immunoresearch 
Secondary Flow cytometry 
Donkey-anti-mouse cy5 Jackson 
Immunoresearch 
Secondary Flow cytometry 
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CHAPTER III 
RESULTS 
 
 
Previous studies in our lab have shown that inhibition of the mTORC1 complex 
with rapamycin inhibits EBV lytic replication in a cell type specific manner25.  This study 
aims to investigate levels of activated phosphorylated proteins in the PI3K-Akt-mTOR 
and MAPK pathways; investigate RKIP and phosphorylated RKIP levels during 
mTORC1 inhibition and lytic replication in epithelial cells and B cells; and determine the 
effects of inhibition of select proteins within those pathways using mTORC1, MEK, and 
p38 inhibitors.  
To investigate levels of phosphorylated activated proteins in the PI3K-Akt-mTOR 
and MAPK pathways, evaluate cell-type specific lytic replication mechanisms, and assess 
levels of RKIP and phosphorylated RKIP in EBV infected epithelial cells and B cells, 
AGS-BDNeo and Raji cells were treated under the conditions listed in Table 1.  Cells 
were then harvested and prepared for flow cytometric analysis or immunoblot analysis.  
Table 3 shows complete list of primary and secondary antibodies used for all experiment. 
To investigate levels of phosphorylated activated proteins downstream of MEK and p38 
in the MAPK pathways, evaluate cell-type specific lytic replication mechanisms, and 
assess whether EBV lytic proteins can be attenuated by blocking the pathways that lead 
to cap-dependent translation, epithelial cells and B cells were treated under the conditions 
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listed in Table 2.  Cells were then harvested and prepared for flow cytometric analysis.  
Table 3 shows complete list of primary and secondary antibodies used. 
 
Levels of Phosphorylated AKT in mTORC1 Inhibited Conditions 
 Levels of phosphorylated AKT and Z protein were measured using flow 
cytometric analysis.  Phosphorylated AKT phosphorylates TSC1/2 which activates 
mTORC1 downstream.  Measuring phosphorylated AKT in relation to Z protein 
expression provides insight into the pathways being utilized by EBV for protein 
translation and lytic replication. 
 Significant increases in total relative Z protein levels were observed in epithelial 
cells for conditions 3 and 4 relative to conditions 1 and 2 (p<0.05) (Figure 6 A).  No 
significant differences were observed in total phosphorylated AKT levels across 
treatment conditions for epithelial cells (Figure 6 A).  Figure 6 B shows the percent totals 
of epithelial cells positive for phosphorylated AKT, Z protein, or both proteins 
simultaneous (double positive).  Conditions 3 and 4 show significant increases in percent 
of epithelial cells positive for Z protein alone relative to conditions 1 and 2 (p<0.05) 
(Figure 6 B).  No significant differences in percent of epithelial cells positive for 
phosphorylated AKT alone or double positive epithelial cells were observed (Figure 6 B).  
Lytic rapamycin treated epithelial cells positive for phosphorylated AKT without Z 
protein only account for approximately 0.2% of cells.  Double positive epithelial cells 
only account for approximately 7% of total lytic rapamycin treated cells.  While Z protein 
in epithelial cells increases with rapamycin treatment, it does not appear to be related to 
phosphorylated AKT levels. 
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 Significant increases in total relative Z protein levels were observed in B cells for 
conditions 3 and 4 relative to conditions 1 and 2 (p<0.05) (Figure 7 A).  The general 
trends of decrease in Z protein levels are observed in lytic cells with rapamycin treatment 
as with other trials.  No significant differences were observed in phosphorylated AKT 
levels across treatment conditions for B cells; however, while Z protein decreases in 
induced cells with rapamycin treatment, phosphorylated AKT levels remain constant 
(Figure 7 A).  Figure 7 B shows the percent of B cells positive for phosphorylated AKT, 
Z protein, or both proteins simultaneous (double positive).  Condition 4 (Figure 7 B) 
shows the general trend of decrease in lytic B cells with rapamycin treatment, however, 
many of the cells that remain lytic despite rapamycin treatment are double positive for 
phosphorylated AKT and Z protein.  In fact, nearly 50% of remaining lytic cells after 
rapamycin treatment are positive for phosphorylated AKT.  Rapamycin treated B cells 
positive for phosphorylated AKT alone account for less than .10% of total lytic cells.  
These observations suggest that phosphorylated AKT levels correspond to Z protein 
levels in B cells that remain lytic after rapamycin treatment. 
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Figure 6. Levels of Z Protein and phospho-AKT in Epithelial Cells Across 
Treatment Conditions for mTORC1 Inhibition. A. Relative epithelial cell Z and 
phospho-AKT levels; Z protein levels significant for conditions 3 and 4 relative to 
conditions 1 and 2 (p<0.05).  B. Percent of epithelial cells positive for Z, phospho-AKT, 
and double positive for Z and phospho-AKT; cells positive for Z protein significant for 
conditions 3 and 4 relative to conditions 1 and 2 (p<0.05).  C. Scatterplots showing 
percent of cells positive for Z, phospho-AKT, or double positive.  All data represent 
means ± SD from biological triplicates.  
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Figure 7. Levels of Z Protein and phospho-AKT in B Cells Across Treatment 
Conditions for mTORC1 Inhibition. A. Relative B cell Z and phospho-AKT levels; Z 
protein levels significant for conditions 3 and 4 relative to conditions 1 and 2 (p<0.05).  
B. Percent of B cells positive for Z, phospho-AKT, and double positive for Z and 
phospho-AKT.  C. Scatterplots showing percent of cells positive for Z, phospho-AKT, or 
double positive.  All data represent means ± SD from biological triplicates. 
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Levels of Phosphorylated AMPK in mTORC1 Inhibited Conditions 
 Levels of phosphorylated AMPK and Z protein were measured using flow 
cytometric analysis.  AMPK is phosphorylated under stress conditions to inhibit 
mTORC1. Measuring phosphorylated AMPK in relation to Z protein expression provides 
insight into the pathways being utilized by EBV for protein translation and lytic 
replication. 
 Significant increases in total relative Z protein levels were observed in epithelial 
cells for conditions 3 and 4 relative to condition 1 (p<0.05) (Figure 8 A).  No significant 
differences were observed in total relative phosphorylated AMPK levels across treatment 
conditions for epithelial cells (Figure 8 A).  Figure 8 B shows the percent totals of 
epithelial cells positive for phosphorylated AMPK, Z protein, or both proteins 
simultaneous (double positive).  Conditions 3 and 4 show significant increases in percent 
of epithelial cells positive for Z protein alone relative to condition 1 (p<0.05) (Figure 8 
B).  No significant differences in percent of epithelial cells positive for phosphorylated 
AMPK alone or double positive epithelial cells were observed (Figure 8 B).  It appears 
that phosphorylated AMPK levels are invariable in epithelial cells during lytic replication 
and rapamycin treatment.  While Z protein in epithelial cells increases with rapamycin 
treatment, it does not appear to be related to phosphorylated AMPK levels. 
 Significant increases in total relative Z protein levels were observed in B cells for 
condition 3 relative to condition 1 (p<0.05) (Figure 9 A).  The general trend of decrease 
in Z protein levels are observed in lytic cells with rapamycin treatment as with other 
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trials.  No significant differences were observed in phosphorylated AMPK levels across 
treatment conditions for B cells; however, while Z protein decreases in lytic cells with 
rapamycin treatment, phosphorylated AMPK levels show trends of increase (Figure 9 A).  
Figure 9 B shows the percent totals of B cells positive for phosphorylated AMPK, Z 
protein, or both proteins simultaneous (double positive).  Condition 4 (Figure 9 B) shows 
the general trend of decrease in lytic B cells with rapamycin treatment.  Approximately 
70% of B cells that remain lytic are double positive for phosphorylated AMPK and Z 
protein (Figure 9 B).  Considering the trends of decrease in Z protein and increase in 
phosphorylated AMPK in rapamycin treated lytic B cells (Figure 9 A, B) and given that 
phosphorylated AMPK is antagonistic of the mTOR pathway, AMPK levels might 
correspond with decreases in Z protein levels when lytic B cells are rapamycin treated.
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Figure 8. Levels of Z Protein and phospho-AMPK in Epithelial Cells Across 
Treatment Conditions for mTORC1 Inhibiton. A. Relative epithelial cell Z and 
phospho-AMPK levels; Z protein levels significant for conditions 3 and 4 relative to 
condition 1 (p<0.05).  B. Percent of epithelial cells positive for Z, phospho-AMPK, and 
double positive for Z and phospho-AMPK; cells positive for Z protein significant for 
conditions 3 and 4 relative to condition 1 (p<0.05).  C. Scatterplots showing percent of 
cells positive for Z, phospho-AMPK, or double positive.  All data represent means ± SD 
from biological triplicates. 
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Figure 9. Levels of Z Protein and phospho-AMPK in B Cells Across Treatment 
Conditions for mTORC1 Inhibition. A. Relative B cell Z and phospho-AMPK levels; Z 
protein levels significant for condition 3 relative to condition 1 (p<0.05).   
B. Percent of B cells positive for Z, phospho-AMPK, and double positive for Z and 
phospho-AMPK; cells positive for Z protein significant for condition 3 relative to 
condition 1 (p<0.05).  C. Scatterplots showing percent of cells positive for Z, phospho-
AMPK, or double positive.  All data represent means ± SD from biological triplicates. 
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Levels of Phosphorylated TSC2 in mTORC1 Inhibited Conditions 
  Levels of phosphorylated TSC2 and Z protein were measured using flow 
cytometric analysis.  Upon phosphorylation, TSC2 loses its inhibitory function over 
Rheb-GTP, thereby allowing activation of mTORC1 downstream.  Measuring 
phosphorylated TSC2 in relation to Z protein expression provides insight into the 
pathways being utilized by EBV for protein translation and lytic replication. 
No significant increases in total relative Z protein levels were observed in 
epithelial cells across treatment conditions in these trials, however, the same general 
trends of increase in Z protein levels during rapamycin treatment are observed as in other 
trials (Figure 10 A).  No significant differences were observed in phosphorylated TSC2 
levels across treatment conditions for epithelial cells (Figure 10 A).  Figure 10 B shows 
the percent totals of epithelial cells positive for phosphorylated TSC2, Z protein, or both 
proteins simultaneous (double positive).  Conditions 3 and 4 show trends of increase in 
percent of epithelial cells positive for Z protein alone (Figure 10 B).  No significant 
differences in percent of epithelial cells positive for phosphorylated TSC2 alone or 
double positive epithelial cells were observed (Figure 10 B).  While the majority of 
phosphorylated TSC2 positive cells are double positive, it appears that phosphorylated 
TSC2 levels are invariable in epithelial cells during lytic replication and rapamycin 
treatment.  While Z protein in epithelial cells increases with rapamycin treatment, it does 
not appear to be related to phosphorylated TSC2 levels. 
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Significant increase in total relative Z protein levels in B cells is observed in 
condition 3 relative to conditions 1 and 2 (p<0.05) (Figure 11 A).  Trends of decrease in 
Z protein levels during rapamycin treatment are observed in lytic B cells (Figure 11A). 
Phosphorylated TSC2 levels show trends of increase in B cells, despite rapamycin 
treatment and decrease in Z protein levels (Figure 11A).  Figure 11 B shows the percent 
totals of B cells positive for phosphorylated TSC2, Z protein, or both proteins 
simultaneous (double positive).  Condition 4 (Figure 11 B) shows the general trend of 
decrease in lytic B cells with rapamycin treatment, however, many of the cells that 
remain lytic despite rapamycin treatment are double positive for phosphorylated TSC2 
and Z protein.  Conditions 3 and 4 for percent of double positive cells are significant 
relative to condition 1 (p<0.05).  Nearly 75% of remaining lytic cells after rapamycin 
treatment are double positive for phosphorylated TSC2 and Z protein (Figure 11 B).  
Rapamycin treated B cells positive for phosphorylated TSC2 alone account for less than 
.10% of total lytic cells (Figure 11 B).  These results suggest that phosphorylated TSC2 
levels correspond to Z protein levels in B cells that remain lytic after rapamycin 
treatment. 
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Figure 10. Levels of Z Protein and phospho-TSC2 in Epithelial Cells Across 
Treatment Conditions for mTORC1 Inhibition. A. Relative epithelial cell Z and 
phospho-TSC2 levels.  B. Percent of epithelial cells positive for Z, phospho-TSC2, and 
double positive for Z and phospho-TSC2.  C. Scatterplots showing percent of cells 
positive for Z, phospho-TSC2, or double positive.  All data represent means ± SD from 
biological triplicates. 
 
 
 
 
 
 
0
0.5
1
1.5
2
2.5
3
3.5
4
Uninduced 5nM Rapamycin Induced Induced + 5nM 
Rapamycin
Relative Z Protein and phospho-
TSC2 Levels in Epithelial Cells
Z Protein phospho-TSC2
A
1                       2                        3                        4  
0
10
20
30
40
50
Uninduced 5nM 
Rapamycin
Induced Induced + 5nM 
Rapamycin
Percent Epithelial Cells with 
Active phospho-TSC2, Z Protein, 
or Simultaneously Active phospho-
TSC2 and Z Protein
Z Protein phospho-TSC2 Both
B
1                     2                      3                      4  
C 
35 
 
 
 
 
 
 
 
Figure 11. Levels of Z Protein and phospho-TSC2 in B Cells Across Treatment 
Conditions for mTORC1 Inhibition. A. B cell Z and phospho-TSC2 levels; Z protein 
values significant for condition 3 relative to conditions 1 and 2 (p<0.05).  B. Percent of B 
cells positive for Z, phospho-TSC2, and double positive for Z and phospho-TSC2; double 
positive conditions 3 and 4 significant relative to condition 1 (p<0.05).  C. Scatterplots 
showing percent of cells positive for Z, phospho-TSC2, or double positive.  All data 
represent means ± SD from biological triplicates. 
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Levels of Phosphorylated mTOR in mTORC1 Inhibited Conditions 
Levels of phosphorylated mTOR and Z protein were measured using flow 
cytometric analysis.  Upon phosphorylation, mTOR phosphorylates downstream targets 
p70S6K and 4EBP1, thereby activating protein synthesis.  Rapamycin does not inhibit 
phosphorylation of mTOR, but instead binds to FKBP12 and prevents phosphorylation of 
downstream targets by mTOR.  Measuring phosphorylated mTOR in relation to Z protein 
expression provides insight into the pathways being utilized by EBV for protein 
translation and lytic replication. 
Significant increases in total relative Z protein levels were observed in epithelial 
cells in conditions 2, 3, and 4 relative to condition 1 (p<0.05) (Figure 12 A).  Figure 12 B 
shows the percent totals of epithelial cells positive for phosphorylated mTOR, Z protein, 
or both proteins simultaneous (double positive).  Condition 4 shows significant increase 
in Z protein levels relative to condition 1 (p<0.05) (Figure 12 B).  Double positive 
epithelial cells for mTOR and Z protein account for approximately 40% of total lytic cells 
in the induced condition (Figure 12 B).  Double positive epithelial cells for mTOR and Z 
protein account for approximately 30% of all lytic epithelial cells during rapamycin 
treatment (Figure 12 B).  Z protein in epithelial cells increases with rapamycin treatment, 
and it appears it may be related to phosphorylated mTOR levels. 
Significant increases in total relative Z protein levels were observed in B cells in 
condition 3 relative to conditions 1 and 2 (p<0.05) (Figure 13 A).  The same general 
trends of decrease in Z protein levels under rapamycin treated and induced conditions in 
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B cells are observed as in other trials (Figure 13 A).  Despite decreases in Z protein levels 
in condition 4, significant increases in phosphorylated mTOR were observed in B cells in 
conditions 3 and 4 relative to conditions 1 and 2 (p<0.05) (Figure 13 A).  Figure 13 B 
shows the percent totals of B cells positive for phosphorylated mTOR, Z protein, or both 
proteins simultaneous (double positive).  Significant increases were observed in double 
positive cells in conditions 3 and 4 relative to conditions 1 and 2 (p<0.05) (Figure 13 B).  
In fact, approximately 61% of remaining lytic cells after rapamycin treatment are double 
positive for phosphorylated mTOR and Z protein (Figure 13 B).  Rapamycin treated B 
cells positive for phosphorylated mTOR alone account for less than .10% of total lytic 
cells (Figure 13 B).  These observations suggest that phosphorylated mTOR levels 
correspond to Z protein levels in B cells that remain lytic after rapamycin treatment. 
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Figure 12. Levels of Z Protein and phospho-mTOR in Epithelial Cells Across 
Treatment Conditions for mTORC1 Inhibition. A. Relative epithelial cell Z and 
phospho-mTOR levels; conditions 2, 3, and 4 significant relative to condition 1.  B. 
Percent of epithelial cells positive for Z, phospho-mTOR, and double positive for Z and 
phospho-mTOR; condition 4 Z protein significant relative to condition 1 (p<0.05).   
C. Scatterplots showing percent of cells positive for Z, phospho-mTOR, or double 
positive.  All data represent means ± SD from biological triplicates. 
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Figure 13. Levels of Z Protein and phospho-mTOR in B Cells Across Treatment 
Conditions for mTORC1 Inhibition. A. B cell Z and phospho-mTOR levels; Z protein 
values significant for condition 3 relative to conditions 1 and 2 (p<0.05).  B. Percent of B 
cells positive for Z, phospho-mTOR, and double positive for Z and phospho-mTOR; 
double positive conditions 3 and 4 significant relative to conditions 1 and 2 (p<0.05).  
C. Scatterplots showing percent of cells positive for Z, phospho-mTOR, or double 
positive.  All data represent means ± SD from biological triplicates. 
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Levels of Phosphorylated p70S6K in mTORC1 Inhibited Conditions 
Levels of phosphorylated p70S6K and Z protein were measured using flow 
cytometric analysis.  Phosphorylation of p70S6K triggers protein synthesis at the 
ribosome.  Measuring phosphorylated p70S6K in relation to Z protein expression 
provides insight into the pathways being utilized by EBV for protein translation and lytic 
replication. 
A significant increase in total relative Z protein level was observed in condition 3 
relative to conditions 1 and 2 in epithelial cells (p<0.05) (Figure 14 A).  Significant 
increase in phosphorylated p70S6k levels for conditions 2 and 3 relative to condition 1 
were observed in epithelial cells (p<0.05) (Figure 14 A).  Trends of increase in 
phosphorylated p70S6K correspond to trends of increase in Z protein (Figure14 A, B).  
Figure 14 B shows the percent totals of epithelial cells positive for phosphorylated 
p70S6K, Z protein, or both proteins simultaneous (double positive).  Significant increase 
in double positive epithelial cells was observed in condition 3 relative to condition 1 
(p<0.05) (Figure 14 B).  Approximately 45% of all lytic epithelial cells in condition 4 are 
double positive for Z protein and phosphorylated p70S6K (Figure 14 B).  These 
observations suggest that phosphorylated p70S6K levels may correspond to Z protein 
levels in epithelial cells. 
Significant increases in total relative Z protein levels were observed in B cells for 
conditions 3 and 4 relative to conditions 1 and 2 (p<0.05) (Figure 15 A).  Trends of 
decrease in Z protein levels during rapamycin treatment were observed (Figure 15 A).  
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While no significant differences in total phosphorylated p70S6K levels were observed in 
B cells, trends of increase across conditions were observed (Figure 15 A).  Figure 15 B 
shows the percent totals of B cells positive for phosphorylated p70S6K, Z protein, or both 
proteins simultaneous (double positive).  Significant increase in double positive B cells 
was observed in condition 3 relative to condition 1 (p<0.05) (Figure 15 B).  
Approximately 52% of all lytic B cells remaining after rapamycin treatment in condition 
4 are double positive for Z protein and phosphorylated p70S6K (Figure 15 B).  These 
observations suggest that phosphorylated p70S6K levels may correspond to Z protein 
levels in B cells that remain lytic after rapamycin treatment, despite decreases in Z 
protein levels.   
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Figure 14. Levels of Z Protein and phospho-p70S6K in Epithelial Cells Across 
Treatment Conditions for mTORC1 Inhibition. A. Relative epithelial cell Z and 
phospho-p70S6K levels; Z protein values significant in condition 3 relative to conditions 
1 and 2; conditions 2 and 3 total relative phospho-p70S6K levels significant relative to 
condition 1 (p<0.05).  B. Percent of epithelial cells positive for Z, phospho-p70S6K, and 
double positive for Z and phospho-p70S6K; condition 4 Z protein significant relative to 
conditions 1 and 2, condition 3 double positive significant relative to condition 1 
(p<0.05).  C. Scatterplots showing percent of cells positive for Z, phospho-p70S6K, or 
double positive.  All data represent means ± SD from biological triplicates. 
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Figure 15. Levels of Z Protein and phospho-p70S6K in B Cells Across Treatment 
Conditions for mTORC1 Inhibition. A. B cell Z and phospho-p70S6K levels; Z protein 
levels significant for conditions 3 and 4 relative to conditions 1 and 2 (p<0.05).   
B. Percent of B cells positive for Z, phospho-p70S6K, and double positive for Z and 
phospho-p70S6K; condition 3 double positive significant relative to condition 1, 
conditions 3 and 4 Z protein only significant to conditions 1 and 2 (p<0.05).  
C. Scatterplots showing percent of B cells positive for Z, phospho-p70S6K, or double 
positive.  All data represent means ± SD from biological triplicates. 
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Levels of Phosphorylated 4EBP1 in mTORC1 Inhibited Conditions 
Levels of phosphorylated 4EBP1 and Z protein were measured using flow 
cytometric analysis.  4EBP1 inhibits eIF4E, a protein that binds 5’ cap of mRNA.  Upon 
phosphorylation, 4EBP1 will release eIF4E, thereby activating cap dependent translation. 
Measuring phosphorylated 4EBP1 in relation to Z protein expression provides insight 
into the pathways being utilized by EBV for protein translation and lytic replication. 
Significant increase was observed in total relative Z protein levels in epithelial 
cells in conditions 3 and 4 relative to conditions 1 and 2 (p<0.05) (Figure 16 A).  
Significant decrease in phosphorylated 4EBP1 level was observed in epithelial cells in 
condition 3 relative to condition 1 (p<0.05) (Figure 16 A).  Figure 16 B shows the 
percent totals of epithelial cells positive for phosphorylated 4EBP1, Z protein, or both 
proteins simultaneous (double positive).  Trends of increase in Z protein was observed in 
conditions 3 and 4 in epithelial cells (Figure 16 B).  Only approximately 10% of all lytic 
epithelial cells in conditions 3 and 4 are double positive for Z protein and phosphorylated 
4EBP1 (Figure 16 B).  These observations suggest that phosphorylated 4EBP1 levels 
may not correspond to Z protein levels in epithelial cells. 
A significant increase in total relative Z protein levels was observed in condition 
3 relative to condition 2 in B cells (p<0.05) (Figure 17 A).  A significant increase in 
phosphorylated 4EBP1 levels were observed in B cells for conditions 3 and 4 relative to 
conditions 1 and 2 (p<0.05) (Figure 17 A).  The same trends of decrease in Z protein 
production in lytic B cells treated with rapamycin are observed as in other trials (Figure 
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17 A).  Figure 17 B shows the percent totals of B cells positive for phosphorylated 
4EBP1, Z protein, or both proteins simultaneous (double positive).  Trends of decrease in 
percent of cells with active Z protein was observed on condition 4 (Figure 17 B).  Double 
positive B cells for phosphorylated 4EBP1 and Z protein were significantly increased in 
conditions 3 and 4 relative to conditions 1 and 2 (p<0.05) (Figure 17 B).  Nearly all cells 
positive for phosphorylated 4EBP1 are also Z positive, and approximately 64% of all 
remaining lytic B cells under rapamycin conditions are double positive (Figure 17 B).  
These trends suggest phosphorylated 4EBP1 may correlate with Z protein production in 
remaining lytic B cells with rapamycin treatment, despite overall decrease in Z protein 
levels.
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Figure 16. Levels of Z Protein and phospho-4EBP1 in Epithelial Cells Across 
Treatment Conditions for mTORC1 Inhibition. A. Epithelial cell Z and phospho-
4EBP1 levels; Z protein level values significant for conditions 3 and 4 relative to 
conditions 1 and 2; phospho-4EBP1 level values significant for condition 3 relative to 1 
(p<0.05). B. Percent of epithelial cells positive for Z, phospho-4EBP1, and double 
positive for Z and phospho-4EBP1.  C. Scatterplots showing percent of cells positive for 
Z, phospho-4EBP1, or double positive.  All data represent means ± SD from biological 
triplicates. 
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Figure 17. Levels of Z Protein and phospho-4EBP1 in B Cells Across Treatment 
Conditions for mTORC1 Inhibition. A. B cell Z and phospho-4EBP1 levels; Z protein 
level values significant for condition 3 relative to condition 2; phospho-4EBP1 level 
values significant for conditions 3 and 4 relative to conditions 1 and 2 (p<0.05).  
B. Percent of B cells positive for Z, phospho-4EBP1, and double positive for Z and 
phospho-4EBP1; double positive conditions 3 and 4 significant relative to conditions 1 
and (p<0.05).  C. Scatterplots showing percent of cells positive for Z, phospho-4EBP1, or 
double positive.  All data represent means ± SD from biological triplicates. 
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Levels of Phosphorylated p38 in mTORC1 Inhibited Conditions 
Levels of phosphorylated p38 and Z protein were measured using flow cytometric 
analysis.  P38 is a MAPK protein that becomes activated during cell stress conditions.  
Upon phosphorylation, p38 phosphorylates Mnk1/2, which in turn activates eIF4E, a 
protein that binds 5’ caps of mRNA and aids in translation.  Measuring phosphorylated 
p38 in relation to Z protein expression provides insight into the pathways being utilized 
by EBV for protein translation and lytic replication. 
Significant differences were observed in total relative Z protein levels in epithelial 
cell in conditions 3 and 4 relative to conditions 1 and 2 (p<0.05) (Figure 18 A).  Trends 
of increase in Z protein levels are observed in rapamycin treated and induced cells as in 
other trials (Figure 18 A).  A trend of increase is observed for phosphorylated p38 levels 
in relation to Z protein levels.  Figure 18 B shows the percent totals of epithelial cells 
positive for phosphorylated p38, Z protein, or both proteins simultaneous (double 
positive).  Significant increases in percent of cells positive for Z protein was observed in 
conditions 3 and 4 relative to conditions 1 and 2 in epithelial cells (p<0.06) (Figure 18 
B).  Approximately 30% of all lytic epithelial cells in conditions 3 and 4 are double 
positive for Z protein and phosphorylated p38 (Figure 18 B).  These observations suggest 
that phosphorylated p38 levels may correspond to Z protein levels in epithelial cells. 
Significant increases in Z protein levels in B cells were observed in conditions 3 
and 4 relative to conditions 1 and 2 (p<0.05) (Figure 19 A).  The same general trends of 
decrease in Z protein levels with rapamycin treatment are observed as in other trials.  
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While no significant changes were observed in total relative p38 levels in B cells, there 
appears to be a trend of increase in p38 in conditions 3 and 4, despite rapamycin 
treatment and decrease in Z protein levels (Figure 19 A).  Figure 19 B shows the percent 
totals of B cells positive for phosphorylated p38, Z protein, or both proteins simultaneous 
(double positive).  Significant increase in percent of cells positive for Z protein was 
observed in condition 3 relative to condition 1 (p<0.05) (Figure 19 B).  While the percent 
of double positive cells for phosphorylated p38 and Z protein are not statistically 
significant, there are trends of increase.  Nearly all the phosphorylated p38 positive cells 
are positive for Z protein as well.  Also, approximately 66% of all remaining lytic cells 
after rapamycin treatment are double positive for Z protein and phosphorylated p38.  
These results suggest that phosphorylated p38 levels may correspond to Z protein levels 
in B cells, and most of the cells that remain lytic after rapamycin treatment are also 
phosphorylated p38 positive.
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Figure 18. Levels of Z Protein and phospho-p38 in Epithelial Cells Across 
Treatment Conditions for mTORC1 Inhibition. A. Epithelial cell Z and phospho-p38 
levels; Z protein level values significant for conditions 3 and 4 relative to 1, and 
condition 3 relative to condition 2 (p<0.05). B. Percent of epithelial cells positive for Z, 
phospho-p38, and double positive for Z and phospho-p38; conditions 3 and 4 for Z 
protein significant relative to conditions 1 and 2 (p<0.05).  C. Scatterplots showing 
percent of cells positive for Z, phospho-p38, or double positive.  All data represent means 
± SD from biological triplicates. 
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Figure 19. Levels of Z Protein and phospho-p38 in B Cells Across Treatment 
Conditions for mTORC1 Inhibition. A. B cell Z and phospho-p38 levels; Z protein 
level values significant for conditions 3 and 4 relative to condition 1 (p<0.05).  B. Percent 
of B cells positive for Z, phospho-p38, and double positive for Z and phospho-p38; Z 
positive condition 3 significant relative to condition 1 (p<0.05).  C. Scatterplots showing 
percent of cells positive for Z, phospho-p38, or double positive.  All data represent means 
± SD from biological triplicates. 
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Levels of Phosphorylated ERK in mTORC1 Inhibited Conditions 
Levels of phosphorylated ERK and Z protein were measured using flow 
cytometric analysis.  ERK is a MAPK protein that becomes activated upon 
phosphorylation via MEK.  Upon phosphorylation, ERK phosphorylates Mnk1/2 and 
TSC1/2, which in turn activates eIF4E, a protein that binds 5’ caps of mRNA and aids in 
translation.  Measuring phosphorylated ERK in relation to Z protein expression provides 
insight into the pathways being utilized by EBV for protein translation and lytic 
replication. 
No significant differences in total relative Z protein levels across treatment 
conditions were observed for epithelial cells, although the same trends of increase in Z 
protein are observed as with other trials (Figure 20 A).  Significant increase in 
phosphorylated ERK levels were observed in epithelial cells in for condition 4 relative to 
condition 1 (p<0.05) (Figure 20 A).  Figure 20 B shows the percent totals of epithelial 
cells positive for phosphorylated ERK, Z protein, or both proteins simultaneous (double 
positive).  No significant increases in percent of cells positive for Z protein was observed; 
however, the general trends of increase in Z protein expression in rapamycin treated 
induced cells are observed as in other trials (Figure 20 B).  The percent of double positive 
cells for conditions 3 and 4 are significantly increased in relation to condition 1 (p<0.05) 
(Figure 20 B).  Approximately 40% of all lytic cells in conditions 3 and 4 are double 
positive for phosphorylated ERK and Z protein (Figure 20 B).  These observations 
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suggest that phosphorylated ERK levels may correspond to increased Z protein levels in 
epithelial cells during mTORC1 inhibition. 
No significant differences in total relative Z protein levels were observed in B 
cells for treatment conditions, observed are the same general trends of decrease in Z 
protein expression with rapamycin treatment is observed as in other trials (Figure 21 A).  
No significant differences in phosphorylated ERK were observed across treatment 
conditions for B cells (Figure 21 A).  However, despite decreases in Z protein levels with 
rapamycin treatment in induced cells, phosphorylated ERK levels increase.  Figure 21 B 
shows the percent totals of B cells positive for phosphorylated ERK, Z protein, or both 
proteins simultaneous (double positive).  No significant changes in percent of cells 
positive for Z protein was observed; however, the general trends of decrease in Z protein 
expression in rapamycin treated induced cells are observed as in other trials (Figure 20 
B).  The percent of double positive cells for condition 4 are significantly increased in 
relation to conditions 1 and 2 (p<0.05) (Figure 21 B).  Approximately 80% of remaining 
lytic cells in rapamycin treated condition 4 are double positive for phosphorylated ERK 
and Z protein (Figure 21 B).   These observations suggest that phosphorylated ERK may 
correspond with Z protein levels in lytic B cells that are rapamycin treated, despite 
decreases in Z protein levels.
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Figure 20. Levels of Z Protein and phospho-ERK in Epithelial Cells Across 
Treatment Conditions for mTORC1 Inhibition. A. Epithelial cell Z and phospho-ERK 
levels; phosphorylated ERK level value significant for condition 4 relative to conditions 1 
and 2 (p<0.05).  B. Percent of epithelial cells positive for Z, phospho-ERK, and double 
positive for Z and phospho-ERK; double positive conditions 3 and 4 significant relative 
to condition 1 (p<0.05).  C. Scatterplots showing percent of cells positive for Z, phospho-
ERK, or double positive.  All data represent means ± SD from biological triplicates. 
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Figure 21. Levels of Z Protein and phospho-ERK in B Cells Across Treatment 
Conditions for mTORC1 Inhibition. A. B cell Z and phospho-ERK levels.  B. Percent 
of B cells positive for Z, phospho-ERK, and double positive for Z and phospho-ERK; 
double positive condition 4 significant relative to conditions 1 and 2 (p<0.05).   
C. Scatterplots showing percent of cells positive for Z, phospho-ERK, or double positive. 
All data represent means ± SD from biological triplicates. 
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Levels of Phosphorylated Mnk1/2 in mTORC1 Inhibited Conditions 
Levels of phosphorylated Mnk1/2 and Z protein were measured using flow 
cytometric analysis.  Mnk1/2 is a MAPK protein that becomes activated upon 
phosphorylation via ERK and p38.  Upon phosphorylation, Mnk1/2 phosphorylates 
eIF4E, which is a protein that binds 5’ caps of mRNA and aids in translation.  Measuring 
phosphorylated Mnk1/2 levels in relation to Z protein expression provides insight into the 
pathways being utilized by EBV for protein translation and lytic replication. 
No significant increases in relative total Z protein levels in epithelial cells were 
observed; however, the general trends of increase in Z protein levels in induced 
rapamycin treated conditions are observed as in other trials.  Significant increases of total 
relative phosphorylated Mnk1/2 levels in epithelial cells were observed in conditions 3 
and 4 relative to condition 1 (p<0.05) (Figure 22 A).  Figure 22 B shows the percent 
totals of epithelial cells positive for phosphorylated Mnk1/2, Z protein, or both proteins 
simultaneous (double positive).  No significant increases in percent of cells positive for Z 
protein were observed; however, the general trends of increase in Z protein expression in 
rapamycin treated induced cells are observed as in other trials (Figure 22 B).  The percent 
of double positive cells for condition 4 are significantly increased in relation to condition 
1 (p<0.05) (Figure 22 B).  Approximately 45% of all lytic cells in conditions 3 and 4 are 
double positive for phosphorylated Mnk1/2 and Z protein (Figure 22 B).  These results 
suggest that phosphorylated Mnk1/2 may correlate with increases in Z protein levels in 
lytic epithelial cells. 
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Significant increase in relative total Z protein levels were observed in B cells in 
condition 3 relative to condition 1 (p<0.05) (Figure 23 A).  Trends of decrease in Z 
protein levels during induction and rapamycin treatment are observed as in other trials 
(Figure 23 A).  Despite decreases in Z protein levels during rapamycin treatment, 
phosphorylated Mnk1/2 values remain constant (Figure 23 A).  Figure 23 B shows the 
percent totals of B cells positive for phosphorylated Mnk1/2, Z protein, or both proteins 
simultaneous (double positive).  Significant increases in percent of cells positive for Z 
protein were observed in condition 3 relative to condition 1 (p<0.05) (Figure 23 B).  The 
percent of double positive cells for conditions 3 and 4 are significantly increased in 
relation to condition 1 (p<0.05) (Figure 23 B).  Approximately 50% of remaining lytic 
cells in rapamycin treated condition 4 are double positive for phosphorylated Mnk1/2 and 
Z protein (Figure 23 B).  These observations suggest that phosphorylated Mnk1/2 may 
correlate with Z protein levels in B cells that remain lytic despite rapamycin treatment 
and overall Z protein decreases. 
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Figure 22. Levels of Z Protein and phospho-Mnk1/2 in Epithelial Cells Across 
Treatment Conditions for mTORC1 Inhibition. A. Epithelial cell Z and phospho-
Mnk1/2 levels; phosphorylated Mnk1/2 level value significant for conditions 3 and 4 
relative to conditions 1 and 2 (p<0.05).  B. Percent of epithelial cells positive for Z, 
phospho-Mnk1/2, and double positive for Z and phospho-Mnk1/2; condition 4 double 
positive significant relative to condition 1 (p<0.05).  C. Scatterplots showing percent of 
cells positive for Z, phospho-Mnk1/2, or double positive.  All data represent means ± SD 
from biological triplicates. 
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Figure 23. Levels of Z Protein and phospho-Mnk1/2 in B Cells Across Treatment 
Conditions for mTORC1 Inhibition. A. C cell Z and phospho-Mnk1/2 levels; Z protein 
level value significant for condition 3 relative to condition 1 (p<0.05).  B. Percent of B 
cells positive for Z, phospho-Mnk1/2, and double positive for Z and phospho-Mnk1/2; 
conditions 3 and 4 double positive values significant relative to condition 1, percent Z 
protein positive cells in condition 3 significant relative to condition 1 (p<0.05).   
C. Scatterplots showing percent of cells positive for Z, phospho-Mnk1/2, or double 
positive.  All data represent means ± SD from biological triplicates. 
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Levels of Phosphorylated eIF4E in mTORC1 Inhibited Conditions 
Levels of phosphorylated eIF4E and Z protein were measured using flow 
cytometric analysis.  eIF4E is a protein that becomes activated upon phosphorylation via 
Mnk1/2 and 4EBP1.  Upon phosphorylation, eIF4E binds 5’ caps of mRNA and aids in 
translation.  Measuring phosphorylated eIF4E levels in relation to Z protein expression 
provides insight into the pathways being utilized by EBV for protein translation and lytic 
replication. 
 Significant increases in Z protein levels were observed in epithelial cells for 
conditions 2 and 4 relative to condition 1 (p<0.05) (Figure 24 A).  The same general 
trends of increase in Z protein levels during lytic replication and rapamycin treatment are 
observed as in other trials.  Significant increase in phosphorylated eIF4E level was 
observed in conditions 4 and 2 relative to condition 1 (p<0.05) (Figure 24 A). Figure 24 
B shows the percent totals of epithelial cells positive for phosphorylated eIF4E, Z 
protein, or both proteins simultaneous (double positive).  No significant increases in 
percent of cells positive for Z protein were observed but the overall trends of increase 
observed as with other trials are seen here (Figure 24 B).  The percent of eIF4E and 
double positive cells appear to increase with Z protein levels. Approximately 60% of lytic 
cells in conditions 3 and 4 are double positive for phosphorylated eIF4E and Z protein 
(Figure 24 B). These observations suggest that phosphorylated eIF4E may correlate with 
Z protein levels in epithelial cells. 
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 No significant levels of Z protein were observed in B cells, but the same general 
trends of increased Z protein under rapamycin treatment are observed as in other trials 
(Figure 25 A).  It appears that phosphorylated eIF4E increases despite lowered levels of 
Z protein in condition 4 (Figure 25 A).  Figure 25 B shows the percent totals of B cells 
positive for phosphorylated eIF4E, Z protein, or both proteins simultaneous (double 
positive).  No significant values in percent of cells positive for Z protein were observed 
but the overall trends of decrease with rapamycin treatment are observed as with other 
trials are seen here (Figure 25 B).  It appears that with decrease in Z protein 
phosphorylated eIF4E levels increase, particularly for cells that are double positive.  In 
fact, approximately 71% of cells expressing Z protein are expressing phosphorylated-
eIF4E as well (Figure 25 B).  This suggest that phosphorylated eIF4E levels correlate to 
Z protein production in lytic B cells, despite rapamycin treatment and Z protein level 
decreases. 
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Figure 24. Levels of Z Protein and phospho-eIF4E in Epithelial Cells Across 
Treatment Conditions for mTORC1 Inhibition. A. Epithelial cell Z and phospho-
eIF4E levels; phosphorylated eIF4E level value significant for conditions 2 and 4 relative 
to condition 1 (p<0.05).  B. Percent of epithelial cells positive for Z, phospho-eIF4E, and 
double positive for Z and phospho-eIF4E.  C. Scatterplots showing percent of cells 
positive for Z, phospho-eIF4E, or double positive.  All data represent means ± SD from 
biological triplicates. 
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Figure 25. Levels of Z Protein and phospho-eIF4E in B Cells Across Treatment 
Conditions for mTORC1 Inhibition. A. B cell Z and phospho-eIF4E levels.  B. Percent 
of B cells positive for Z, phospho-eIF4E, and double positive for Z and phospho-eIF4E.  
C. Scatterplots showing percent of cells positive for Z, phospho-eIF4E, or double 
positive.  All data represent means ± SD from biological triplicates. 
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Levels of RKIP and Phosphorylated RKIP in mTORC1 Inhibited Conditions 
Levels of RKIP and phosphorylated RKIP along with Z protein were measured 
using western blot analysis.  RKIP is an inhibitor of the MAPK protein ERK by binding 
to its upstream activator, Raf.  Upon phosphorylation, RKIP loses its ability to inhibit Raf 
and becomes active as a modulator of other pathways such as the NF-κβ and GPCR 
pathways.  RKIP and phosphorylated RKIP’s role in relation to EBV lytic replication is 
not well defined.  Measuring RKIP and phosphorylated RKIP levels in relation to Z 
protein expression provides insight into the pathways being utilized by EBV for protein 
translation and lytic replication. 
Figure 26 A shows the western blot image for phosphorylated RKIP, RKIP and Z 
protein in epithelial cells. There was no significant difference in observed levels of Z 
protein in epithelial cells amongst treatment conditions (Figure 26 B).  There were trends 
of increased Z protein levels in lytic epithelial cells treated with rapamycin as in other 
trials.  No significant variability in RKIP or phosphorylated RKIP was observed.  It 
appears that RKIP and phosphorylated RKIP levels do not correspond to Z protein levels 
in epithelial cells, but further investigation may be necessary. 
Figure 27 A shows the western blot image for phosphorylated RKIP, RKIP and Z 
protein in B cells.  Z Protein levels were significantly increased in condition 3 relative to 
condition 1 (p<0.05) (Figure 27 B).  No significant differences in RKIP were observed 
amongst conditions.  Phosphorylated RKIP was significantly increased in condition 2 
relative to condition 1 (p<0.05) (Figure 27 B).  There are trends of increase in 
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phosphorylated RKIP levels in rapamycin treated condition 4.  It is possible that 
phosphorylated RKIP plays a role in the observed response of EBV in B cells to 
rapamycin treatment; however, further investigation may be necessary.   
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Figure 26. Western Blot Analysis for phospho-RKIP, RKIP 
and Z Protein Levels in Epithelial Cells Across Conditions 
for mTORC1 Inhibition. A. Imaging for epithelial cell western 
blot analysis.  B. Graphical representation of quantified protein 
bands.  All data represent means ± SD from biological 
triplicates. 
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Figure 27. Western Blot Analysis for phospho-RKIP, RKIP, 
and Z Protein Levels in B Cells Across Conditions for 
mTORC1 Inhibition. A. Imaging for B cell western blot 
analysis.  B. Graphical representation of quantified protein 
bands; condition 2 phospho-RKIP values significant relative to 
condition 1 (p<0.05), condition 3 Z protein levels significant 
relevant to condition 1 (p<0.05).  All data represent means ± SD 
from biological triplicates. 
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Levels of Z Protein and Phosphorylated TSC2 in mTORC1, MEK, and p38 Inhibited 
Conditions 
Levels of phosphorylated TSC2 and Z protein were measured using flow 
cytometric analysis.  Upon phosphorylation, TSC2 loses its inhibitory function over 
Rheb-GTP, thereby allowing activation of mTORC1 downstream.  TSC2 can be 
phosphorylated by AKT and ERK.  Measuring phosphorylated TSC2 in relation to Z 
protein expression during mTORC1 and MAPK protein inhibition provides insight into 
the pathways being utilized by EBV for protein translation and lytic replication. 
In epithelial cell trials for Z protein and phosphorylated TSC2 levels during 
mTORC1, MEK, and p38 inhibited conditions, significant decrease in Z protein level was 
observed in condition 5 relative to condition 1 and condition 11 relative to condition 10 
(p<0.05) (Figure 28).  While levels of Z protein and phosphorylated TSC2 levels showed 
trends of decrease in conditions 3 and 6 relative to condition 1, these trends were not 
statistically significant.  Levels of Z protein and phosphorylated TSC2 increased across 
all other conditions with significant p-values (p<0.05) for conditions 8, 9, 10, 12, 13, 14, 
15, and 16 relative to condition 1 (p<0.05) (Figure 28).  In general, epithelial cell 
conditions treated with rapamycin increase in Z protein levels and phosphorylated TSC2 
levels.  It also appears that even though attenuation of EBV lytic replication is not 
possible with the use of the inhibitors, p38 seems to be the inhibitor treatment that 
provides the most drastic decrease in Z protein and phosphorylated TSC2 levels in 
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epithelial cells.  This suggests EBV utilizes the p38 MAPK pathway in addition to the 
mTOR pathway in epithelial cells for translation of viral proteins. 
In B cell trials for Z protein and phosphorylated TSC2 levels during mTORC1, 
MEK, and p38 inhibited conditions, significant decrease in Z protein level was observed 
in condition 3 relative to 2, and conditions 10, 11, and 12 relative to condition 9 (p<0.05) 
(Figure 29).  Significant decrease in phosphorylated TSC2 level was observed in 
condition 5 relative to condition 1.  Significant increase in Z protein levels was observed 
in conditions 6, 9, and 11 relative to condition 1 (p<0.05) (Figure 29).  While not 
significant, trends of decrease in phosphorylated TSC2 levels were observed in 
conditions with MEK inhibitor, due to the inhibition of phosphorylation of TSC2.  
Rapamycin decreased Z protein levels just as in other trials, but the increases in 
phosphorylated TSC2 are observed just as in the mTORC1 inhibited trials.  Combinations 
of multiple inhibitors in conditions 14, 15, and 16 increased Z protein levels and 
phosphorylated TSC2 (Figure 29).  The mechanism by which EBV translates its proteins 
under these conditions is not known, as EBV requires cap-dependent translation for 
protein synthesis, and condition 16 blocks all the pathways.  It appears the MEK inhibitor 
decreased Z protein levels in lytic B cells more than rapamycin treatment; and the MEK 
inhibitor treatment provided a significant decrease relative to the induced condition.  This 
suggests that EBV uses the MAPK MEK and ERK pathway in B cells in addition to the 
mTORC1 pathway. 
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Figure 28. Levels of Z Protein and phospho-TSC2 in Epithelial Cells Across 
Treatment Conditions for mTORC1, p38, and MEK Inhibition.  Epithelial cell Z and 
phospho-TSC2 levels.   Significant decrease in Z protein levels observed in condition 5 
relative to condition 1 and condition 11 relative to condition 10 (p<0.05).  Significant 
increases in Z protein levels observed in conditions 8, 9, 10, 12, 13, 14, 15, and 16 
relative to condition 1 (p<0.05).  All data represent means ± SD from biological 
triplicates. 
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Figure 29. Levels of Z Protein and phospho-TSC2 in B Cells Across Treatment 
Conditions for mTORC1, p38, and MEK Inhibition.  B cell Z and phospho-TSC2 
levels.  Significant decrease in Z protein levels observed in condition 3 relative to 
condition 2 and conditions 10, 11, and 12 relative to condition 9 (p<0.05).  Significant 
increase in Z protein levels observed in conditions 6, 9, and 11 relative to condition 1 
(p<0.05).  Significant decrease in phospho-TSC2 levels observed in condition 5 relative 
to condition 1 (p<0.05).  All data represent means ± SD from biological triplicates.   
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Levels of Z Protein and Phosphorylated mTOR in mTORC1, MEK, and p38 Inhibited 
Conditions 
Levels of phosphorylated mTOR and Z protein were measured using flow 
cytometric analysis.  mTOR becomes activated downstream of Rheb-GTP when TSC2 
becomes phosphorylated.  TSC2 can be phosphorylated via Akt or ERK.  Upon 
phosphorylation, mTOR will phosphorylated p70S6K and 4EBP1 which are involved in 
protein synthesis.  Measuring phosphorylated mTOR in relation to Z protein expression 
during mTORC1 and MAPK protein inhibition provides insight into the pathways being 
utilized by EBV for protein translation and lytic replication. 
The results for epithelial cell trials for Z protein and phosphorylated mTOR levels 
during mTORC1, MEK, and p38 inhibited conditions mirrors the results of 
phosphorylated TSC2 levels because TSC2 phosphorylates mTOR.  Significant decreases 
in Z protein levels are observed in conditions 2 and 3 relative to condition 1, and 
condition 11 relative to condition 10 (p<0.05) (Figure 30).  Significant increases in Z 
protein levels are observed in conditions 10, 12, 13, 14, 15, and 16 relative to condition 1 
(p<0.05) (Figure 30).  Amongst all other conditions, there were no significant observed 
decreases in Z protein levels.  Observed levels of phosphorylated mTOR were 
significantly decreased in condition 2 relative to condition 1 (p<0.05) (Figure 30).  
Amongst all other conditions, there were no significantly lowered levels of 
phosphorylated mTOR.  Inhibitor combinations in conditions 12, 13, 14, 15, and 16 
triggered increased Z protein expression for reasons not understood (Figure 30).  For this 
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data set, it appears that p38 inhibition attenuates viral lytic replication the most 
effectively, which suggests that EBV uses the p38 MAPK pathway in addition to the 
mTOR pathway for translation of viral proteins.   
The results for B cell trials for Z protein and phosphorylated mTOR levels during 
mTORC1, MEK, and p38 inhibited conditions mirror the results for phosphorylated 
TSC2 trial because TSC2 phosphorylates mTOR.  Statistically significant increase in Z 
protein levels were observed in conditions 11 and 14 relative to condition 1 (p<0.05) 
(Figure 31).  Statistically significant increases in phosphorylated mTOR levels were 
observed in conditions 2, 6, 7, 9, 10, 11, 14, and 15 relative to condition 1 (p<0.05) 
(Figure 31).  While no statistically significant decrease in Z protein level was observed, 
there are trends of decrease in conditions 12 and 13 (Figure 31).  Rapamycin decreased Z 
protein levels just as in other trials, but the increases in phosphorylated mTOR are 
observed just as in the mTORC1 inhibited trials.  Combinations of multiple inhibitors in 
conditions 14, 15, and 16 increased Z protein levels and phosphorylated mTOR (Figure 
31).  The mechanism by which EBV translates its proteins under these conditions is not 
known, as EBV requires cap-dependent translation for protein synthesis, and condition 16 
blocks all pathways.  It appears the p38 and MEK inhibitors decreased Z protein levels in 
lytic B cells more than rapamycin treatment; this suggests that EBV uses the MAPKs p38 
and ERK pathways in addition to the mTORC1 pathway.  The MEK inhibitor was most 
effective at attenuating Z protein in B cells, suggesting MEK may be the more 
predominate route of EBV for protein translation and replication in B cells. 
74 
 
  
 
Figure 30. Levels of Z Protein and phospho-mTOR in Epithelial Cells Across 
Treatment Conditions for mTORC1, p38, and MEK Inhibition.  Epithelial cell Z and 
phospho-mTOR levels.  Significant decreases in Z protein levels observed in conditions 2 
and 3 relative to condition 1 and condition 11 relative to condition 10 (p<0.05).  
Significant increases in Z protein levels observed in conditions 10, 12, 13, 14, 15, and 16 
relative to condition 1 (p<0.05).  Significant decrease in phospho-mTOR level observed 
in condition 2 relative to condition 1 (p<0.05).  All data represent means ± SD from 
biological triplicates. 
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Figure 31. Levels of Z Protein and phospho-mTOR in B Cells Across Treatment 
Conditions for mTORC1, p38, and MEK Inhibition.  B cell Z and phospho-mTOR 
levels.  Significant increase in Z protein levels were observed in conditions 11 and 14 
relative to condition 1 (p<0.05).  Significant increase in phospho-mTOR levels were 
observed in conditions 2, 6, 7, 9, 10, 11, 14, and 15 relative to condition 1 (p<0.05).  All 
data represent means ± SD from biological triplicates. 
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Levels of Z Protein and Phosphorylated ERK in mTORC1, MEK, and p38 Inhibited 
Conditions 
Levels of phosphorylated ERK and Z protein were measured using flow 
cytometric analysis.  Upon phosphorylation, ERK phosphorylates TSC2 and Mnk1/2, 
which in turn go on to activate proteins involved in cap-dependent translation and protein 
synthesis.  Measuring phosphorylated ERK in relation to Z protein expression during 
mTORC1 and MAPK protein inhibition provides insight into the pathways being utilized 
by EBV for protein translation and lytic replication. 
In epithelial cell trials for Z protein and phosphorylated ERK levels during 
mTORC1, MEK, and p38 inhibited conditions, no significant decreases in Z protein 
levels are observed. Significant increases in Z protein levels are observed in conditions 
10, 11, 12, 13, 14, 15, and 16 relative to condition 1 (p<0.05) (Figure 32).  Decrease in Z 
protein levels were observed in condition 11 relative to condition 10.  Levels of 
phosphorylated ERK were not significantly altered by use of inhibitors, but a trend of 
decrease was observed in the MEK inhibited condition 12.  Trends of Z protein decrease 
were most extensive in the p38 inhibited condition 11 (Figure 32).  These data suggest 
EBV use of p38 for Z protein production in addition to the mTOR pathway in epithelial 
cells.  
In B cell trials for Z protein and phosphorylated ERK levels during mTORC1, 
MEK, and p38 inhibition, Z protein levels were not significantly decreased amongst any 
of the conditions.  Significant increases in Z protein levels were observed in conditions 9, 
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10, 11, 12, 14, 15, and16 relative to condition 1 (p<0.05) (Figure 33).  Levels of 
phosphorylated ERK we not significantly decreased amongst any of the conditions, but 
trends of decrease were seen in conditions 11, 12, and 13 (Figure 33).  The MEK 
inhibitor treatment in condition 12 decreased Z protein levels most drastically.  This 
suggests the use of the MEK/ERK MAPK pathways for lytic replication in B cells. 
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Figure 32. Levels of Z Protein and phospho-ERK in Epithelial Cells Across 
Treatment Conditions for mTORC1, p38, and MEK Inhibition.  Epithelial cell Z and 
phospho-ERK levels. Significant increase in Z protein levels observed in conditions 10, 
11, 12, 13, 14, 15, and 16 relative to condition 1 (p<0.05).  All data represent means ± SD 
from biological triplicates. 
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Figure 33. Levels of Z Protein and phospho-ERK in B Cells Across Treatment 
Conditions for mTORC1, p38, and MEK Inhibition.  B cell Z and phospho-ERK 
levels. Significant increase in Z protein levels observed in conditions 9, 10, 11, 12, 14, 
15, and16 relative to condition 1 (p<0.05).  All data represent means ± SD from 
biological triplicates. 
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Levels of Z Protein and Phosphorylated Mnk1/2 in mTORC1, MEK, and p38 Inhibited 
Conditions 
Levels of phosphorylated Mnk1/2 and Z protein were measured using flow 
cytometric analysis.  Mnk1/2 is a MAPK protein that becomes activated upon 
phosphorylation via ERK and p38.  Upon phosphorylation, Mnk1/2 phosphorylates 
eIF4E, which is a protein that binds 5’ caps of mRNA and aids in translation.  Measuring 
phosphorylated Mnk1/2 levels in relation to Z protein expression provides insight into the 
pathways being utilized by EBV for protein translation and lytic replication. 
In epithelial cell trials for Z protein and phosphorylated Mnk1/2 levels during 
mTORC1, MEK, and p38 inhibited conditions, no significant decreases in Z protein 
levels were observed. Significant increases in Z protein levels are observed in conditions 
7, 9, 10, 12, 14, 15, and 16 relative to condition 1 (p<0.05) (Figure 34).  Significant 
increases in levels of phosphorylated Mnk1/2 were observed in conditions 12, 15, and a6 
(p<0.05) (Figure 34).  A trend of decrease in Z protein and phosphorylated Mnk1/2 was 
observed in the p38 inhibited condition 11 (Figure 34).  This suggests EBV uses the p38 
MAPK pathway for Z protein production in addition to the mTOR pathway in epithelial 
cells.  
In B cell trials for Z protein and phosphorylated Mnk1/2 levels during mTORC1, 
MEK, and p38 inhibited conditions observed levels of Z protein were significantly 
decreased in condition 3 relative to condition 2, conditions 12, 13, 14, 15, and 16 relative 
to condition 9, and conditions 12, 13, 14, 15, and 16 relative to condition 11 (p<0.05) 
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(Figure 35).  Significant increase in Z protein levels were observed in conditions 6, 7, 8, 
9, and 11 relative to condition 1 (p<0.05) (Figure 35).  Levels of phosphorylated Mnk1/2 
were significantly decreased in condition 13 relative to condition 10 (p<0.05) (Figure 35).  
Levels of phosphorylated Mnk1/2 were significantly increased in conditions 9, 10, 11, 12, 
13, 14, 15, 16 relative to condition 1 (p<0.05).  It appears conditions 12 and 13 with 
MEK and p38 inhibitors most drastically inhibits Z protein and phosphorylated Mnk1/2 
levels in these trials.  These data suggest EBV utilizes p38 and MEK MAPKs for protein 
translation and lytic replication in addition to mTOR in B cells.
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Figure 34. Levels of Z Protein and phospho-Mnk1/2 in Epithelial Cells Across 
Treatment Conditions for mTORC1, p38, and MEK Inhibition.  Epithelial cell Z and 
phospho-Mnk1/2 levels.  Significant increases in Z protein levels observed in conditions 
7, 9, 10, 12, 14, 15, and 16 relative to condition 1 (p<0.05).  Significant increase in levels 
of phospho-Mnk1/2 observed in conditions 12, 15, and 16 (p<0.05).  All data represent 
means ± SD from biological triplicates. 
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Figure 35. Levels of Z Protein and phospho-Mnk1/2 in B Cells Across Treatment 
Conditions for mTORC1, p38, and MEK Inhibition.  B cell Z and phospho-Mnk1/2 
levels.  Significant increase in Z protein level observed in conditions 9 and 11 relative to 
condition 1 (p<0.05).  Significant decrease in Z protein level observed in condition 3 
relative to condition 2, conditions 12, 13, 14, 15, and 16 relative to condition 9, and 
conditions 12, 13, 14, 15, and 16 relative to condition 11 (p<0.05).  Significant increase 
in Z protein levels observed in conditions 6, 7, 8, 9, and 11 relative to condition 1 
(p<0.05).  Significant increase in phospho-Mnk1/2 observed in conditions 9, 10, 11, 12, 
13, 14, 15, 16 relative to condition 1 (p<0.05).  Significant decrease in phospho-Mnk1/2 
levels observed in condition 13 relative to condition 10 (p<0.05).  All data represent 
means ± SD from biological triplicates. 
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Levels of Z Protein and Phosphorylated eIF4E in mTORC1, MEK, and p38 Inhibited 
Conditions 
Levels of phosphorylated eIF4E and Z protein were measured using flow 
cytometric analysis.  eIF4E is a protein that becomes activated upon phosphorylation via 
Mnk1/2 and 4EBP1.  Upon phosphorylation, eIF4E binds 5’ caps of mRNA and aids in 
translation.  Measuring phosphorylated eIF4E levels in relation to Z protein expression 
provides insight into the pathways being utilized by EBV for protein translation and lytic 
replication. 
In epithelial cell trials for Z protein and phosphorylated eIF4E levels during 
mTORC1, MEK, and p38 inhibited conditions no significant decreases in Z protein levels 
were observed amongst conditions.  Significant increases in Z protein levels were 
observed in conditions 4, 7, 9, 10, 11, 12, 13, 14, 15, and 16 relative to condition 1 
(p<0.05) (Figure 36).  No significant decreases in phosphorylated eIF4E levels were 
observed.  Significant increases in phosphorylated eIF4E were observed in conditions 7, 
8, 15, and 16 relative to condition 1 (p<0.05) (Figure 36).  The most extensive decrease in 
Z protein and phosphorylated eIF4E levels was observed in the p38 inhibited condition 
11 (Figure 36).  This suggests EBV utilizes the p38 MAPK pathways for lytic replication 
in addition to the mTOR pathway. 
In B cell trials for Z protein and phosphorylated eIF4E levels during mTORC1, 
MEK, and p38 inhibited conditions no significant decreases in Z protein levels were 
observed.  Significant increases in Z protein levels were observed in conditions 9, 10, 11, 
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12, and, 14 relative to condition 1 (p<0.05) (Figure 37).  The same general trends of Z 
protein decrease with rapamycin treatment of lytic B cells is observed as in other trials.  
Significant increase in phosphorylated eIF4E levels were observed in conditions 10, 11, 
14, 15, and 16 relative to condition 1 (p<0.05) (Figure 37).  The most drastic inhibition 
regarding both Z protein levels and phosphorylated eIF4E was the MEK inhibitor in 
condition 13.  This suggests EBV utilizes MEK in the MAPK pathway in addition to 
mTORC1 in B cells, and that EBV lytic replication is dependent on phosphorylated 
eIF4E. 
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Figure 36. Levels of Z Protein and phospho-eIF4E in Epithelial Cells Across 
Treatment Conditions for mTORC1, p38, and MEK Inhibition.  Epithelial cell Z and 
phospho-eIF4E levels.  Significant increase in Z protein levels observed in conditions 4, 
7, 9, 10, 11, 12, 13, 14, 15, and 16 relative to condition 1 (p<0.05).  Significant increase 
in phospho-eIF4E observed in conditions 7, 8, 15, and 16 relative to condition 1 (p<0.05).  
All data represent means ± SD from biological triplicates. 
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Figure 37. Levels of Z Protein and phospho-eIF4E in B Cells Across Treatment 
Conditions for mTORC1, p38, and MEK Inhibition.  B cell Z and phospho-eIF4E 
levels.  Significant increase in Z protein levels observed in conditions 9, 10, 11, 12, and, 
14 relative to condition 1 (p<0.05).  Significant increase in phospho-eIF4E levels 
observed in conditions 10, 11, 14, 15, and 16 relative to condition 1 (p<0.05).  All data 
represent means ± SD from biological triplicates. 
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CHAPTER IV 
DISCUSSION 
 
The PI3K-Akt-mTOR and MAPK pathways are major pathways used by 
eukaryotic cells to integrate various environmental and nutritional signals for cell growth, 
metabolism, and protein synthesis.  It is well established that EBV, and all other DNA 
viruses, utilize host cellular cap-dependent translational machinery to produce viral gene 
products.  Based on previous studies, it is known that EBV lytic replication varies 
amongst B cells and epithelial cells when mTORC1 in the PI3K-Akt-mTOR pathway is 
inhibited with rapamycin.  Levels of Z protein, an immediate early lytic protein, decrease 
in B cells during rapamycin treatment.  Despite rapamycin treatment in epithelial cells, 
levels of Z protein increase.  Based on this knowledge, this study aimed to investigate the 
cell-type specific responses of EBV protein production during inhibition of the mTORC1 
complex.  Phosphorylated protein levels within the PI3K-Akt-mTOR and MAPK 
pathways were analyzed during inhibition of the mTORC1 complex, as well as during 
inhibition of the MAPK proteins MEK and p38.  Flow cytometric and western-blot 
analyses were conducted to investigate levels of phosphorylated proteins within these 
pathways in relation to Z protein levels.  
Levels of phosphorylated Akt, AMPK, and TSC2 proteins in the PI3K-Akt-
mTOR pathways were found to be invariable during EBV lytic replication and rapamycin 
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treatment in epithelial cells (Figures 6, 8, 10).  Levels of phosphorylated 4EBP1 in the 
PI3K-Akt-mTOR pathway significantly decreased during lytic induction of epithelial 
cells and remained at low levels during rapamycin treatment, despite increase in Z protein 
levels (Figure 16).  These data suggest that the mechanism by which EBV produces lytic 
gene product, Z, may not heavily involve phosphorylated Akt, AMPK, TSC2, or 4EBP1 
in the PI3K-Akt-mTOR pathway.  Activation of these proteins does not appear to be 
related to the increases in Z protein levels observed during lytic replication and 
rapamycin treatment in epithelial cells.  Levels of phosphorylated mTOR, and p70S6K in 
the PI3K-Akt-mTOR pathway, as well as p38, ERK, and Mnk1/2 in the MAPK 
pathways, appear to increase during EBV lytic replication in epithelial cells (Figures 12, 
14, 18, 20, and 22).  These data suggest that the mechanism by which EBV produces lytic 
gene product, Z, may involve phosphorylated mTOR, p70S6K, p38, and Mnk1/2 during 
lytic replication in epithelial cells.  Activation of these proteins appears to increase as Z 
protein levels increase during lytic replication and rapamycin treatment in epithelial cells.  
These data suggest activation of these proteins may be involved in the cell-type specific 
response observed with rapamycin treatment in epithelial cells.  The common target 
protein of the PI3K-Akt-mTOR and MAPK pathways, eIF4E, appears to increase in 
phosphorylation during lytic replication and rapamycin treatment in epithelial cells 
(Figure 24).  This is the protein that binds 5’ cap of mRNA, and thus appears to be related 
to Z protein expression levels during lytic replication.  Increase in levels of 
90 
 
phosphorylated eIF4E appear to relate to increases in Z protein levels during rapamycin 
treatment of lytic epithelial cells. 
In the epithelial cell treatments of MEK, p38, and mTORC1 inhibition, it appears 
the p38 inhibitor provides the most drastic decrease in Z protein levels during lytic 
replication (Figures 28, 30, 32, 34, and 36).  These data suggest p38 may play a role in Z 
protein levels observed during lytic replication of EBV in epithelial cells.  It is possible 
that EBV in epithelial cells is more heavily reliant on p38 activation for lytic replication 
and synthesis of viral gene products.  Also, it was observed that lytic replication cannot 
be attenuated with blockage of the pathways that lead to activation of eIF4E and cap-
dependent translation.  Furthermore, the conditions that included rapamycin treatment 
showed increases in Z protein levels, despite being treated with MEK and p38 inhibitor 
combinations.  This suggests that lytic replication and synthesis of viral gene products 
during mTORC1 inhibition can continue, and even increase, despite blockage of 
alternative MAPK pathways.  The underlying mechanism by which this occurs remains 
to be elucidated.  
Figure 38 shows the proposed predominant pathways utilized by EBV in 
epithelial cells.  Based on the experimental data, it appears EBV utilizes the MAPK 
proteins p38 and MEK during lytic replication.  It appears that Z protein level increases 
during rapamycin treatment in epithelial cells may correspond to levels of phosphorylated 
proteins in the MAPK pathways; p38, MEK, ERK, and Mnk1/2, to activate the common 
downstream target of the MAPK and PI3K-Akt-mTOR pathways, eIF4E. 
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RKIP and phosphorylated RKIP levels do not appear to be drastically influenced 
by lytic replication and rapamycin treatment in epithelial cells (Figure 26).  Levels of 
these proteins do not appear to correspond to levels of Z protein.  In B cells, however, it 
appears that phosphorylated RKIP levels increase during lytic replication and even during 
rapamycin treatment in B cells (Figure 27).  It is possible that levels of phosphorylated 
RKIP may play a role in the Z protein levels observed in lytic B cells that remain after 
rapamycin treatment.  A better understanding of the relationship between RKIP and 
phosphorylated RKIP with Z protein expression could be developed with further 
experimental investigation.  Coimmunoprecipitation studies could assist in identifying 
how much RKIP is bound to Raf in epithelial cells and B cells during the cell-type 
specific responses identified during lytic replication and rapamycin treatment.  Also, 
treatment of epithelial cells and B cells with RKIP siRNA could shed light on RKIP’s 
role in EBV lytic replication mechanisms and the observed cell-type specific responses. 
It appears that EBV in B cells utilizes a more broad-range approach to activation 
of eIF4E.  Levels of phosphorylated Akt, TSC2, mTOR, p70S6K, and 4EBP1 in the 
PI3K-Akt-mTOR pathway appear to increase with lytic replication of EBV in B cells. 
(Figures 7, 11, 13, 15, 17).  Despite Z protein level decrease in B cells during rapamycin 
treatment, the phosphorylated levels of these proteins remain constant or even increase.  
These data suggest these proteins may play a role in B cells that are still lytic and 
expressing Z protein despite rapamycin treatment.  Levels of phosphorylated AMPK 
decrease in B cells with rapamycin treatment (Figure 9).  Because AMPK is a stress-
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responsive negative regulator in the PI3K-Akt-mTOR pathway, these data suggest a role 
of phosphorylated AMPK in the cell-type specific response of observed decreases in Z 
protein levels with rapamycin treatment in B cells.  In addition to proteins in the PI3K-
Akt-mTOR pathway, it appears EBV utilizes MAPK proteins in B cells for lytic 
replication and synthesis of lytic proteins.  Levels of phosphorylated p38, ERK, and 
Mnk1/2 increase during lytic replication of EBV in B cells (Figures 19, 21, and 23).  
Levels of these phosphorylated proteins remain constant or even increase during 
rapamycin treatment, suggesting phosphorylation of these proteins may correspond to 
levels of Z protein and cells that remain lytic despite rapamycin treatment. The common 
target protein of the PI3K-Akt-mTOR and MAPK pathways, eIF4E, appears to increase 
in phosphorylation during lytic replication and rapamycin treatment in B cells (Figure 
25).  This is the protein that binds 5’ cap of mRNA, and thus appears to be related to Z 
protein expression levels during lytic replication.  Increase in levels of phosphorylated 
eIF4E appear to relate to Z protein levels during lytic replication in B cells, as well as 
during rapamycin treatment.  While rapamycin decreases total lytic Z protein levels in B 
cells, it does not fully attenuate viral lytic replication.  It appears the remaining refractory 
lytic cells are still producing Z protein due to the abundant activation of these proteins in 
the PI3K-Akt-mTOR and MAPK pathways. 
In the B cell treatments of MEK, p38, and mTORC1 inhibition, it appears the 
MEK inhibitor provides the most drastic decrease in Z protein levels during lytic 
replication (Figures 29, 31, 33, 35, and 37).  These data suggest MEK may play a role in 
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Z protein levels observed during lytic replication of EBV in B cells.  It was also observed 
that lytic replication cannot be attenuated with blockage of the pathways that lead to 
activation of eIF4E and cap-dependent translation.  In fact, conditions that combined 
inhibitors produced increases in Z protein levels during lytic replication. The underlying 
mechanism by which this occurs remains to be elucidated.  
Figure 38 shows the proposed predominant pathways utilized by EBV in B cells.  
Based on the experimental data, it appears EBV utilizes a very broad range of proteins 
within the PI3K-Akt-mTOR and MAPK pathways in B cells during lytic replication.  It 
appears that increases in phosphorylated AMPK may play a role in the cell-type specific 
response of EBV to mTORC1 inhibition in B cells.  It also appears that Z protein level 
increases despite rapamycin treatment in B cells may correspond to levels of 
phosphorylated proteins in the PI3K-Akt-mTOR and MAPK pathways; Akt, TSC2, 
mTOR, p70S6K, 4EBP1, p38, MEK, ERK, and Mnk1/2, to activate the common 
downstream target of the MAPK and PI3K-Akt-mTOR pathways, eIF4E. 
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Figure 38. Proposed Predominant Pathways Utilized by EBV in B Cells and 
Epithelial Cells.  Epithelial cell EBV network shown in green regions; B cell EBV 
network shown in blue regions 
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